Starting an All-Oral Longer Regimen in a Primary Multidrug-Resistant Pulmonary Tuberculosis Patient at a District Tuberculosis Center for the First Time: A Rare Case.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

1. BPaLM Regimen Against Drug-Resistant Tuberculosis in India: A Need of the Hour.Cureus · 2024
   Article
2. Primary Rifampicin Mono-Resistant Extrapulmonary Tuberculosis of the Scapula With Cold Abscesses: A Report of a Rare Case.Cureus · 2024
   Article
3. Multidrug-Resistant Tuberculosis of the Spine With Bilateral Psoas and Pre- and Paravertebral Abscesses in an Immunocompetent Indian Female With Multiple Adverse Drug Reactions: The World's First Report.Cureus · 2024
   Article
4. Iliac Bone Tuberculosis Presenting as Left Thigh Swelling in an Indian Female Patient: A Rare Case.Cureus · 2022
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as